Search Results

Join NCF for Oct2024. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page Join us Friday, October 18th at 1:00 PM Pacific to hear renowned liver and pancreas surgeon Dr. Gagandeep “Gaugs” Singh discuss the evolving algorithms in the management of NET liver metastases. Dr. Singh, Chief of Surgical Oncology at City of Hope® Cancer Center in Phoenix, asks the question whether it is prudent to be aggressive surgically, or if it is all about timing and strategy. There will be a live Q&A session immediately following his presentation. Please submit your general questions on surgical interventions of liver metastases into the Slido submission form below. SUBMIT YOUR QUESTIONS *Submit your non-case specific questions below. ABOUT GAGANDEEP SINGH, M.D., F.A.C.S. Internationally renowned liver and pancreas surgeon Gagandeep “Gaugs” Singh, M.D., F.A.C.S., is Chief of Surgical Oncology and Director of Surgical Services at City of Hope® Cancer Center Phoenix. A seasoned health care leader with more than 20 years’ experience building outstanding surgical teams, Dr. Singh is excited to return to Phoenix – where he completed part of his medical training – and to City of Hope, where he spent a decade as the chief of City of Hope Duarte’s surgical oncology program. In the clinic, Dr. Singh takes a thoughtful yet forceful approach to treating cancers of the liver, pancreas and gastrointestinal systems. As a health care leader, he is passionate about empowering teams to achieve their fullest potential. He has been recognized with numerous awards and leadership positions. After beginning his faculty academic career at the Keck School of Medicine at the University of Southern California in Los Angeles, Dr. Singh was appointed director of the Liver and Pancreas Center at the John Wayne Cancer Institute in Santa Monica, California, where he also served as chair of the Cancer Committee. At City of Hope Duarte, Dr. Singh spearheaded the liver and pancreatic cancer programs and led the Division of Surgical Oncology to national recognition. He has been included on multiple lists of “America’s Top Surgeons,” “Best Doctors of America,” “Super Doctors” and “Top Doctors of America.” Dr. Singh earned his medical degree from the Mahatma Gandhi Institute of Medical Sciences in India, before training at multiple internationally renowned cancer centers, including Tata Memorial Hospital and Cancer Center in Bombay, René Descartes University in Paris and the Royal Liverpool University Hospital in the United Kingdom, as well as the Marion Bessin Liver Center at the Albert Einstein College of Medicine in New York, Maricopa Medical Center in Phoenix and the University of Iowa. A board-certified surgeon, diplomate of the American Board of Surgery and fellow of the American College of Surgeons, Dr. Singh is an internationally recognized expert in his field and a member of the National Comprehensive Cancer Network for Hepatobiliary Cancers, the group that sets the guidelines for the standard of care for hepatobiliary cancers. As a researcher, Dr. Singh has written on topics such as complex liver resections for liver metastases, management algorithms for neuroendocrine tumors, vascular reconstructions with difficult pancreatic surgery for pancreatic cancer and advanced robotic surgery. His work on robotic surgery has been presented at the Society of Surgical Oncology, America’s Hepato-Pancreato-Biliary Association, the Society of Laparoscopic & Robotic Surgeons and other national meetings. An innovator at heart, he is in constant pursuit of enhancing the surgical experience and developing technical innovations in liver and pancreatic surgery. He has collaborated with engineers from the California Institute of Technology and Harvey Mudd College and has several invention disclosures and patents to his name. Dr. Singh’s translational research includes projects with molecular biologists, X-ray crystallographers, structural chemists and super-resolution scientists across the City of Hope national system. The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by LACNETS or the sponsors of this program. LACNETS does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS REGISTER

BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors << Back BRAVESST2: A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors IDENTIFIER ( ClinicalTrials.gov ) : NCT07129252 DRUG/TREATMENT : CRN09682 PHASE : 1/2 STATUS : Recruiting SPONSOR : Crinetics Pharmaceuticals, Inc. Download the BRAVESST2 Study Brochure here >>> DESCRIPTION: BRAVESST-2 is a Phase 1/2, first-in-human clinical trial studying a new investigational medication called CRN09682. This treatment is designed for people with metastatic or locally advanced neuroendocrine tumors (NETs), neuroendocrine carcinomas (NECs), or other solid tumors that express somatostatin receptor type-2 (SST2). What is CRN09682? CRN09682 is a potential new antibody-drug conjugate (ADC) that is given by intravenous (IV) infusion. It is designed to: Recognize and attach to SST2-positive cancer cells, and Deliver a cancer-fighting drug (MMAE) directly to those cells The goal is to slow or stop tumor growth while limiting exposure to healthy cells. Why This Study Matters This study aims to understand: Safety — what side effects occur and at what doses Tolerability — how participants handle the medication How the drug behaves in the body Early signs of effectiveness in SST2-expressing tumors Because this is a first-in-human study, CRN09682 has not yet been approved by any regulatory authority. Who Can Join You may be eligible if you: Are 18 years or older Have progressive, metastatic, or locally advanced NET, NEC, or another SST2-positive solid tumor Examples include: pancreatic, lung, or GI NETs; small or large cell lung cancer; extra-pulmonary NEC; colorectal, gastric, breast, hepatocellular, nasopharyngeal carcinomas; Merkel cell carcinoma; and melanoma Crinetics_BRAVESST2_Bi-fold Par… Have not had surgery in the last 90 days Have not received prior treatment with MMAE-based therapies Your study team will confirm your full eligibility. What Participation Involves Screening period: up to 28 days IV treatment every 21 days (Cycle 1, then additional cycles) Safety follow-up: 30 days after the last dose Long-term follow-up: every 3 months Optional tumor biopsies What to Expect The study drug, lab tests, imaging, and all study procedures are provided at no cost Travel expenses may be reimbursed You may stop participation at any time For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT Name: Crinetics Clinical Trials Phone Number: 833-276-4636 Email: clinicaltrials@crinetics.com This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.

Join NCF for Zeal. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page REGISTER Location CinemaWest Beach Cities 4DX, ScreenX & Giant Screen with Laser831 S Nash StEl Segundo, CA 90245 Parking The open lot behind the cinema is the closest, free parking as is the structure attached to it. There is handicapped parking in both and a ramp from the first level of the structure to the theater entrance/patio. Event Schedule & Comfort Tips Saturday’s forecast in El Segundo is a high of 74°F and a low of 59°F . The Mix & Mingle portion of the event will take place outdoors on Pink’s Patio, so we recommend bringing a light layer as the evening cools, and the theater may be cooler inside. 2:30 PM - 3:30 PM – Light savory & sweet bites served on Pink's Patio outside the theater 3:45 PM – Final arrival for screening & last chance to grab your concessions 4:00 PM – Zeal for Life Introduction by Rain Bennett & Screening (90 minutes) 5:30 PM – 'Continuing the Conversation' - Q&A With Dr. Aman Chauhan, Lisa Yen, Rain Bennett, and Dusty Hurley Check-In Please check in at the Neuroendocrine Cancer Foundation registration table when you arrive and be sure to pick up your complimentary Popcorn & Soda/Water Voucher. Regrets If you're unable to make it, please email Heather Davis at Heather@NCF.net . For additional questions, please contact Heather@NCF.net . We look forward to sharing this meaningful afternoon with you. ABOUT Join the Neuroendocrine Cancer Foundation on Saturday afternoon, March 7th, for a special screening of Zeal for Life . To see firsthand what makes those living with neuroendocrine cancer, the experts who treat them, and their caregivers - zealous. Optimism, determination, and wholehearted dedication collectively contribute to longevity and living with zeal! Coping and navigating a cancer diagnosis can be daunting and fraught with overwhelm and misunderstanding, but in this film we take a moment to appreciate when gaps are bridged and connections made to exponentially affect change. This documentary focuses on how patients & caregivers, medical experts and patient advocacy organizations work collectively to better navigate and manage neuroendocrine cancer. The Carcinoid Cancer Foundation recognized this need nearly 60 years ago. For decades, CCF has connected patients with physicians who know and appreciate neuroendocrine tumors. They made evidence-based education accessible to physicians and patients alike. Through many avenues and efforts, CCF has driven awareness, study and understanding of this uncommon disease. This poignant and illuminating film delves into the lives of individuals and families navigating the insidious realm of Neuroendocrine Cancer, or Neuroendocrine Tumor (NET)—an uncommon and notoriously complex treatment, often misdiagnosed or diagnosed after metastasis. Through intimate interviews and compelling spotlight the extraordinary resilience of NET patients, caregivers and the experts who care for them is captured. THANKS TO OUR SPONSORS T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments.

CAREFNDR: Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen << Back CAREFNDR: Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen IDENTIFIER ( ClinicalTrials.gov ) : NCT07087054 DRUG/TREATMENT : Paltusotine PHASE : 3 STATUS : Recruiting SPONSOR : Crinetics Pharmaceuticals Inc. https://www.youtube.com/watch?v=b6Jnzj9Epng CAREFNDR Presentation Slides .pdf Download PDF • 1.60MB DESCRIPTION: A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors. The purpose of this study is to continue the evaluation of the safety, efficacy, and pharmacokinetics (PK) of paltusotine in participants with carcinoid syndrome. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. MORE INFORMATION Download the CAREFNDR flyer here >>> For more information about the CAREFNDR clinical study, visit CAREFNDR.com/ncf . Global enrollment in CAREFNDR is expected throughout 2025 and 2026. Read this recent press release: " Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome" CONTACT Crinetics Clinical Trials EMAIL: clinicaltrials@crinetics.com PHONE: 833-276-4636 This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.

IDE849 (DLL3-targeted ADC) ± Durvalumab in DLL3+ Tumors << Back A Study of IDE849 in Patients with DLL3 Expressing Tumors Including Small Cell Lung Cancer IDENTIFIER ( ClinicalTrials.gov ) : NCT07174583 DRUG/TREATMENT : IDE849, an anti-DLL3 antibody-drug conjugate PHASE : 1/2 STATUS : Recruiting SPONSOR : IDEAYA Biosciences DESCRIPTION: This is a Phase 1/2, multi-center clinical trial studying a new treatment called IDE849 in people with DLL3-expressing cancers, including small cell lung cancer (SCLC), high-grade neuroendocrine carcinomas (NECs), and other solid tumors. What is DLL3? DLL3 (delta-like ligand 3) is a protein found on the surface of some cancer cells, especially high-grade neuroendocrine cancers. Because DLL3 is much less common on normal cells, it has become an important target for new cancer treatments. What is IDE849? IDE849 is an antibody-drug conjugate (ADC), a newer type of targeted cancer therapy. ADCs combine: an antibody, which acts like a homing device to find cancer cells with a specific marker (like DLL3), and a drug payload (often a chemotherapy-like agent) that is delivered directly to those cells IDE849 is designed to find DLL3-positive cancer cells and deliver a cancer-fighting drug directly to them, which may help kill cancer cells while limiting damage to healthy tissue. In this study, IDE849 is being tested: on its own, and in combination with other treatments, including durvalumab (an immunotherapy) or another investigational drug (IDE161) About the Study Researchers want to understand: Safety and side effects How well the treatment works How the drug moves through and affects the body (pharmacokinetics and immunogenicity) The best dose to use in future studies How the Study is Structured Part 1 (Dose Escalation): Participants receive increasing doses of IDE849 (alone or in combination) The goal is to find the safest and most effective dose Part 2 (Dose Expansion): Participants receive the selected dose(s) Researchers further evaluate safety and early effectiveness in specific groups of patients Who This Study Is For This study is enrolling people with: Small cell lung cancer (SCLC) High-grade neuroendocrine carcinomas (NECs) Other solid tumors that express DLL3 Why This Matters Treatment options for high-grade neuroendocrine carcinomas (NECs) and small cell lung cancer (SCLC) are often limited, especially after standard therapies stop working. DLL3-targeted therapies like IDE849 represent a promising new approach because they are designed to specifically target cancer cells that carry the DLL3 marker. By delivering treatment directly to these cells, this strategy may improve effectiveness while limiting damage to healthy tissue. This study is also exploring combination approaches, including immunotherapy, which may further enhance how well treatment works. If successful, this research could help expand treatment options for patients with DLL3-positive cancers, including those beyond small cell lung cancer. CONTACT For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. Name: IDEAYA Clinical Trials Phone Number: +1-855-433-2246 Email: IDEAYAClinicalTrials@ideayabio.com This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.

Lu-177 DOTATATE vs Everolimus in Lung NETs << Back Randomized Phase II Trial of Lutetium Lu-177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors DRUG/TREATMENT: LUTETIUM LU-177 DOTATATE (PRRT) + (EVEROLIMUS) CLINICALTRIALS.GOV IDENTIFIER: NCT04665739 PHASE: 2 STATUS: Recruiting SPONSOR: National Cancer Institute (NCI) https://www.youtube.com/watch?v=v8Ev1_8DVdo Dr. Suki Padda Discusses Lu177 Dotatate in Lung NETs https://www.youtube.com/watch?v=Z6ky87smo-I Dr. Heloisa Soares Discusses Lu-177 Dotatate in Lung NETs DESCRIPTION: This phase II trial studies the effect of lutetium Lu-177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in the body (advanced). Radioactive drugs, such as lutetium Lu-177 dotatate, may carry radiation directly to tumor cells and may reduce harm to normal cells. Lutetium Lu-177 dotatate may be more effective than everolimus in shrinking or stabilizing advanced bronchial neuroendocrine tumors. For more information on eligibility criteria, trial locations, study details, etc. go to ClinicalTrials.gov to view this trial here. PRINCIPAL INVESTIGATORS: Thomas A. Hope, MD, UCSF Sukhmani K. Padda, MD, Cedars Sinai Medical Center, Los Angeles, California CONTACT: This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.

<< Go back to the Podcast page EPISODE 30: BONE & BRAIN METASTASES IN NEUROENDOCRINE CANCER Download a Transcript of this Episode >> ABOUT THIS EPISODE When and how often do NETs spread to the bones or brain? How are they found? What is the treatment? Dr. Robert Ramirez of Vanderbilt University addresses concerns surrounding bone metastases (or “mets”) as well as rare brain metastases. MEET DR. ROBERT RAMIREZ, DO, FACP Dr. Robert Ramirez is a medical oncologist specializing in the treatment of thoracic and neuroendocrine malignancies and an Associate Professor of Medicine at Vanderbilt University Medical Center in Nashville, TN. He earned his medical degree from the University of Medicine and Dentistry of New Jersey School of Osteopathic Medicine. He completed an internal medicine residency at Cooper University Hospital in Camden, New Jersey. He then completed a hematology and medical oncology fellowship at the University of Tennessee Health Sciences Center in Memphis, Tennessee and served as chief fellow. He is a Fellow of the American College of Physicians, and a member of American Society of Clinical Oncology, the International Association for the Study of Lung Cancer (IASLC), and the North American Neuroendocrine Tumor Society (NANETS). He serves on the Board of Directors for NANETS as well as the Scientific Review and Research Committee. His clinical and research interests include neuroendocrine tumors (NETs) and lung cancer. He has a specific interest in NETs of the lung ranging from diffuse idiopathic pulmonary neuroendocrine tumor cell hyperplasia (DIPNECH) and carcinoid tumors to small cell lung cancer and other high-grade neuroendocrine carcinomas. He is active in clinical trial design including investigator-initiated trials. He enjoys teaching residents and fellows and has multiple publications and given many lectures for the scientific community on the topics of NETs and lung cancers. TOP TEN QUESTIONS Bone mets: 1. When and how often do NETs spread to the bones? 2. Where in the bones are tumors? What does it mean when NETs spread to the bones? How does this compare to other cancers? 3. How are bone spots found and monitored? Should they be biopsied? 4. What is the treatment for bone mets? Should I have radiation? Would radiation limit my ability to get PRRT? 5. Should I be on bone strengthening medication? Am I at higher risk for fractures (or breaking my bones) if I have NETs in the bones? 6. Do bone mets respond to PRRT? 7. Does having bone mets put me at a higher risk of MDS? Brain mets: 8. When and how often do NETs spread to the brain? Do all types of NETs have the potential to spread to the brain? 9. How are brain mets found and monitored? When should I suspect this? 10. How are brain mets treated? What does having brain mets mean for my life? *Bonus: What final words of hope do you have for the neuroendocrine cancer community? RESOURCES WATCH https://www.youtube.com/watch?v=eC5OGO6VvEE LISTEN LACNETS Lung NET Resources DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

<< Back Surgery Trials SWOG S2104: Adjuvant CAPTEM for High Risk pNET SWOG 2408: Lanreotide vs Placebo Before Surgery to Prevent Pancreatic Fistula

<< Go back to the Podcast page EPISODE 22: WHAT TO KNOW ABOUT PANCREATIC NETS Download a Transcript of this Episode >> ABOUT THIS EPISODE What is the difference between Pancreatic Neuroendocrine Tumor (PNET) and Pancreatic Cancer? Where exactly is the pancreas located and why is the tumor location important? NET Oncologist Dr. Jennifer Chan from Dana-Farber Cancer Institute takes us through how some treatments, imaging and blood work are unique to PNETs. She also expounds on several ongoing and active trials. MEET DR. JENNIFER CHAN Jennifer Chan, MD, MPH is an Associate Professor of Medicine at Harvard Medical School and Institute Physician in the Division of Medical Oncology at Dana-Farber Cancer Institute in Boston, MA. She focuses her clinical practice on the care of patients with neuroendocrine tumors and gastrointestinal cancers. Dr. Chan is the Director of the Program in Neuroendocrine and Carcinoid Tumors and Clinical Director for the Gastrointestinal Cancer Center at the Dana-Farber/Brigham and Women's Cancer Center. She has been principal investigator of multiple clinical trials investigating novel therapies for neuroendocrine tumors and has been involved in studies examining factors associated with clinical outcomes in patients with neuroendocrine tumors. Dr. Chan is a past chair of the Guidelines Committee of the North American Neuroendocrine Tumor Society (NANETS) and serves on the National Comprehensive Cancer Network (NCCN) Neuroendocrine Tumors Guidelines Panel. She is a member of the Neuroendocrine Tumor Taskforce of the National Cancer Institute and the Board of Directors of NANETS. TOP 10 QUESTIONS 1. What are pancreatic NETs? Where are they located? 2. How are pancreatic NETs found? What are the symptoms of a pancreatic NET? 3. How is pancreatic NETs different from “pancreatic cancer?” How is it different from a pancreatic cyst? 4. What types of labs, scans, or testing is done to determine if someone has a pancreatic NET? 5. What are some ways that pancreatic NETs differ from other types of NETs? What makes it unique? 6. How do you decide if the pancreatic NET can be surgically removed? What type of surgeon would make that determination? 7. How are pancreatic NETs treated medically (or nonsurgically)? How are treatments sequenced? 8. How are the treatments different from other NETs? 9. How are pancreatic NETs monitored? What types of bloodwork or tests should be done and how often should they be done? What is the best type of scan for pancreatic NETs? 10. What are clinical trials we should be aware of or exciting new treatments in the pipeline for pancreatic NETs? RESOURCES https://www.youtube.com/watch?v=2H_SChk3gxw "CABINET Trial - Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors Video Introduction" - Jennifer Chan https://www.youtube.com/watch?v=HHtDAQzDj9E "Update on NET Clinical Trials" with Dr. Heloisa Soares (Recorded March 10, 2023) https://www.youtube.com/watch?v=ozTjElpHiyQ "NET Medical Therapies & Clinical Trials" with Dr. Reidy-Lagunes - LACNETS 2022 LACNETS Annual Conference (Recorded June 18, 2022 ) https://www.youtube.com/watch?v=sZIVip3CIxI Systemic Therapy: GI, Lung, PNETS & Unknown Primary" - LACNETS 2020 Virtual NET Conference ( Recorded June 20, 2020 ) https://www.youtube.com/watch?v=u9-iTXz8G2Y NET Patient Mary's Story https://www.youtube.com/watch?v=ncemqQ_vhMI NET Patient Tom's Story https://www.youtube.com/watch?v=Mm7tQpqoxBU NET Caregiver Gilda's Story https://www.youtube.com/watch?v=aZtVzVO-JO0 NET Patient Federico's Story LISTEN LACNETS Podcast Episode 5: "Treatment for NETs" with Dr. Randy Hecht LACNETS Podcast Episode 7: "Imaging of NETs" with Dr. Gary Ulaner LACNETS Podcast Episode 11: "Pathology for NETs" with Dr. Sue Chang LACNETS Podcast Episode 19: "Beyond the Basics: The Pathology of NET" with Dr. Andrew M. Bellizzi NETWise Podcast Episode 10: Pancreatic NETs + Take the Quiz READ 2020 The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors 2020 The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors CABINET Trial - Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

Join NCF for Feb2026. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=nrbsUI54nEM Some Topics Covered: Neuroendocrine, NET, clinical trials, PRRT, RLT, neoadjuvant trials, adjuvant trials, metastatic NET, symptom control Download the slides >>> ABOUT Join us for an overview of the latest clinical trials in neuroendocrine cancer with Dr. Heloisa Soares, a medical oncologist and physician-scientist at the Huntsman Cancer Institute (HCI) in Salt Lake City. Dr. Soares will walk through key neuroendocrine cancer clinical trials including what they are studying, what makes them exciting, and how they may shape future treatment options. She will also explain why clinical trials matter, how they benefit patients, and what to consider when exploring whether a trial might be right for you. Whether you’re a patient, caregiver, or simply trying to stay informed, this webinar will provide clear, practical insights to help you better understand emerging research and what it means for the neuroendocrine cancer community. The presentation will focus on current NET clinical trials. For information on NEC clinical trials, go to our high grade resources page: https://www.ncf.net/high-grade-nen-resources . ABOUT DR. HELOISA P. SOARES Medical Oncologist Huntsman Cancer Institute (HCI) University of Utah Dr. Heloisa Soares is a medical oncologist who focuses on neuroendocrine cancers. She is an associate professor at the Huntsman Cancer Institute (HCI) at the University of Utah, where she is also the Medical Director for the Clinical Trials Office. Nationally, she serves as the NCI NET task force co-chair and the chair of the North American Neuroendocrine Tumor Society (NANETS) inaugural NET Patient Action Team of the NETPact Committee. She also recently served as a member of the directors for NANETS. Dr. Soares is a passionate advocate for patients. You can follow her on Twitter at @helops79 RESOURCES https://www.youtube.com/watch?v=cmKEuKfOcGw The Latest on Immunotherapy for Neuroendocrine Cancer with Dr. Aman Chauhan (Dec 2025) Additional Clinical Trials Resources: https://www.ncf.net/clinical-trials/additional-resources https://www.youtube.com/watch?v=CXW71vedhIw "Navigating Clinical Trials: Expectations vs. Realities" with Taymeyah Al-Toubah • Aug 2023 https://www.youtube.com/watch?v=Kf3p_j5tFVU Clinical Trials: Why, What & How • Josh Mailman • 2023 Patient Education Conference THANKS TO OUR SPONSORS T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments.

<< Go back to the Podcast page EPISODE 40: NEN TREATMENTS: FOCUS ON EXTERNAL RADIATION THERAPY Download a Transcript of this Episode >>> ABOUT THIS EPISODE What is radiation oncology, and how is it used for neuroendocrine cancer? UCSF radiation oncologists Dr. Will Chen and Dr. Alexandra Hotca-Cho describe external radiation therapy (SBRT) and how, when, and where it may be used for select patients with neuroendocrine cancers. They address common concerns about the planning process, safety concerns, and treatment sequencing. MEET DR. WILLIAM C. CHEN Dr. William C. Chen is a radiation oncologist and translational researcher. Dr. Chen received his undergraduate degree from Johns Hopkins University and completed medical school at the University of California, San Francisco. He completed his internal medicine preliminary internship at Kaiser San Francisco, followed by a residency in Radiation Oncology at UCSF. He is a Chan Zuckerburg Biohub Physician Scientist Fellow and a Helen Diller Family Cancer Center Physician Scientist Program in Clinical Oncology (PSPCO) Fellow. His research focuses on biomarker development, informatics, and clinical trial development with a focus on meningiomas and other malignancies of the central nervous system and beyond. MEET DR. ALEXANDRA HOTCA-CHO Dr. Hotca specializes in treating gastrointestinal cancers, with expertise in advanced radiation therapy techniques such as intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), stereotactic body radiation therapy (SBRT), and respiratory gating. These approaches are designed to optimize treatment outcomes and minimize side effects. Her research focuses on enhancing patient quality of life through preventive strategies and identifying predictive biomarkers for radiation-induced toxicities. Dr. Hotca is dedicated to providing exceptional care to the diverse patient community at UCSF. TOP TEN QUESTIONS ABOUT EXTERNAL RADIATION THERAPY: 1. What is radiation oncology? How does it work? How is it different from other types of radiation? 2. What are the types of radiation therapies used for neuroendocrine cancer? 3. Which neuroendocrine cancers are they used for, and when are they used? How do you decide who is a good candidate and if it will be effective? Where in the body can SBRT be used? (bone, liver, pancreas, rectal?) Where can it not be used in the body, and when is SBRT NOT used? Is there a number or size limit of the tumor(s)? 4. For Bone: How do NETs affect the bones? Are they “on” or “in” the bone, and does the tumor tend to weaken it? If given to the bone, does SBRT weaken the bone? What are the chances of fracture with radiation to the bone? Does it matter which area of the bone/body is treated? What other factors influence fracture risk? (age, dose, number of treatments)? Should patients have a bone density scan before SBRT? If bone lesions are causing pain, how soon after treatment might a patient expect to have pain alleviated? How common is increased pain after treatment to the bone? What causes that? 5. Safety: How much radiation is given with these procedures? Is there a concern about radiation safety following the procedures? (Do patients need to avoid others in the hours or days after the treatment?) Is there a lifetime limit to the amount of radiation one can receive, especially considering surveillance CT & PET scans? How often can these procedures be repeated? Does it damage other tissues or organs? How common are secondary cancers? What types and how treatable are they? Is there a risk with fertility? What other risks are there? 6. How do these therapies compare to PRRT or radioembolization in terms of safety? If someone has had PRRT or radioembolization, can they also receive radiation therapy to the liver or bones? Is there increased risks if someone has had PRRT, radioembolization or CAPTEM or alkylating agents? 7. Is there an optimal sequence for treatments? 8. What is SBRT like for patients? What is the planning and preparation process? How do you determine how many treatments and what dose to give? 9. What does the patient experience during and after the procedure? Does it hurt? What are the side effects? How much time do I need to take off of work? 10. How effective is SBRT in terms of managing symptoms? How effective is SBRT in controlling or destroying the tumor? How do you know if the treatment “worked”? Bonus: What is the future of radiation therapy in neuroendocrine cancer treatment? RESOURCES READ Stereotactic Ablative Radiotherapy for the Management of Liver Metastases from Neuroendocrine Neoplasms: A Preliminary Study DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

COMPOSE: PRRT with Lu-177 EDOTREOTIDE versus “Standard of Care” in Well-Differentiated Aggressive G2 & G3 GEP-NETs << Back ITM (COMPOSE) Phase III Clinical Trial: 177 LU-EDOTREOTIDE VS. Best Standard of Care in Well-Differentiated Aggressive G2 & G3 GEP-NETs CLINICALTRIALS.GOV IDENTIFIER: NCT04919226 DRUG/TREATMENT: 177Lu-Edotreotide PRRT (Peptide Receptor Radionuclide Therapy) PRRT versus CAPTEM (Capecitabine and Temozolomide), Everolimus or FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin) PHASE: 3 STATUS: Recruiting SPONSOR: ITM https://www.youtube.com/watch?v=r1hmEzrooxE Dr. Heloisa Soares Discusses COMPOSE: PRRT -LU-177 EDOTREOTIDE https://www.youtube.com/watch?v=w9kA8_gmVfM Dr. Will Pegna Discusses COMPOSE: PRRT - LU-177 EDOTREOTIDE Starting at 9:04 UPDATE (March 2025) https://www.youtube.com/watch?v=H0H1RNwIwV0 The Neuroendocrine Cancer Foundation @NCFCancer (previously @LACNETS) interviews Mayo Clinic Medical Oncologist and #NetCancer expert Dr. Thor Halfdanarson at the 2025 ENETS Annual Medical and Scientific Conference in Krakow, Poland (March 5-7, 2025). Dr. Halfdanarson shares the breaking news of positive results from ITM’s phase 3 COMPETE trial, the first prospective, randomized phase 3 study comparing PRRT with an active treatment (everolimus). DESCRIPTION: ITM is sponsoring “COMPOSE,” an international phase III clinical study to evaluate the efficacy, safety and impact on quality of life of Targeted Radionuclide Therapy (PRRT) with no-carrier-added lutetium-177-edotreotide (n.c.a. 177Lu-edotreotide) compared to a standard therapy with either CAPTEM or everolimus or FOLFOX, in patients with well-differentiated advanced Grade 2 and Grade 3, somatostatin receptor-positive (SSTR+) neuroendocrine tumors of gastroenteric or pancreatic origin (G2 and G3 GEP-NETs). The study is being conducted predominantly in Europe, North America, India and Australia, in approximately 10 countries and 40 sites. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: Dr. Nicolas Schneider or Amanda Rotger at ITM EMAIL: info-solucin@itm-radiopharma.com